Sugi Predict

Sugi Predict / Compounds / SCHEMBL2946216

SCHEMBL2946216

SCHEMBL2946216

N#Cc1nc(Br)ccc1O

nearest known ligand 0.34

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ NQO2 P16083 1/20 0.34
▸ ESR1 P03372 1/20 0.33
▸ ESR2 Q92731 1/20 0.33
▸ SOS2 Q07890 1/20 0.32
▸ USP7 Q93009 1/20 0.32
▸ USP47 Q96K76 1/20 0.32
▸ ERBB2 P04626 1/20 0.32
▸ MEN1 O00255 1/20 0.31
▸ TTR P02766 1/20 0.31
▸ ALB P02768 1/20 0.31
▸ KMT2A Q03164 1/20 0.31
▸ CA12 O43570 1/20 0.30
▸ CA2 P00918 1/20 0.30
▸ CA3 P07451 1/20 0.30
▸ CA6 P23280 1/20 0.30
▸ CA9 Q16790 1/20 0.30
▸ CA14 Q9ULX7 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19715553 0.77 MBOAT4 (0.35) USP7USP47ERBB2
SCHEMBL13291191 0.76 SOS2 (0.50) ESR1ESR2SOS2USP7USP47
SCHEMBL13291167 0.74 ALDH1A1 (0.33) ESR1ESR2SOS2USP7USP47
SCHEMBL13291169 0.74 ESR1 (0.33) ESR1ESR2SOS2USP7USP47
SCHEMBL13291163 0.74 ALDH1A1 (0.45) MEN1KMT2A
SCHEMBL31395201 0.74 CHEK1 (0.34) USP7ERBB2MEN1KMT2A
SCHEMBL29498654 0.74 USP8 (0.36) USP7USP47ERBB2
SCHEMBL3719102 0.74 KDM4E (0.37) USP7USP47ERBB2KMT2A
SCHEMBL22129397 0.74 CHEK1 (0.34) USP7ERBB2MEN1KMT2A
SCHEMBL12665887 0.74 PIK3CD (0.33) ERBB2MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 77 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12377083-B2 Lysophosphatidic acid receptor antagonist and preparation method therefor WUHAN LL SCIENCE AND TECHNOLOGY DEVELOPMENT CO., LTD. (CN) 2025-08-05 — — US disclosed
US-20250215029-A1 STAT MODULATORS AND USES THEREOF RECLUDIX PHARMA, INC. 2025-07-03 — — US disclosed
EP-4463459-A1 STAT MODULATORS AND USES THEREOF Recludix Pharma, Inc. (US) 2024-11-20 — — EP disclosed
CN-118804917-A STAT modulators and uses thereof 瑞克鲁迪克斯制药股份有限公司 2024-10-18 — — CN disclosed
WO-2023133336-A1 STAT MODULATORS AND USES THEREOF RECLUDIX PHARMA, INC. (US) 2023-07-13 — — WO disclosed
WO-2023133336-A1 STAT MODULATORS AND USES THEREOF RECLUDIX PHARMA, INC. (US) 2023-07-13 — — WO disclosed
EP-3152210-B1 TANK-BINDING KINASE INHIBITOR COMPOUNDS GILEAD SCIENCES INC (US) 2023-07-05 — — EP disclosed
EP-3152210-B1 TANK-BINDING KINASE INHIBITOR COMPOUNDS GILEAD SCIENCES INC (US) 2023-07-05 — — EP disclosed
WO-2023116390-A1 PYRIMIDINE-2(1H)-ONE-FUSED BICYCLIC COMPOUND HAVING MAT2A INHIBITORY ACTIVITY AND USE THEREOF 上海海和药物研究开发股份有限公司 2023-06-29 — — WO disclosed
US-20220079928-A1 LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONIST AND PREPARATION METHOD THEREFOR WUHAN LL SCIENCE AND TECHNOLOGY DEVELOPMENT CO., LTD. (CN) 2022-03-17 — — US disclosed
US-20150344473-A1 TANK-BINDING KINASE INHIBITOR COMPOUNDS GILEAD SCIENCES, INC. (US) 2015-12-03 — — US disclosed
US-20150344473-A1 TANK-BINDING KINASE INHIBITOR COMPOUNDS GILEAD SCIENCES, INC. (US) 2015-12-03 — — US disclosed
US-20150011531-A1 INHIBITORS OF HIV REPLICATION BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2015-01-08 — — US disclosed
US-20150011531-A1 INHIBITORS OF HIV REPLICATION BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2015-01-08 — — US disclosed
WO-2013091096-A1 CONDENSED TRICLYCLIC COMPOUNDS AS INHIBITORS OF HIV REPLICATION BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2013-06-27 — — WO disclosed
US-7737161-B2 Condensed furan compounds MITSUBISHI TANABE PHARMA CORPORATION (JP) 2010-06-15 — — US disclosed
US-20090156803-A1 Condensed furan compounds KAWAGUCHI TAKAYUKI 2009-06-18 — — US disclosed
US-7514449-B2 Fused furan compound MITSUBISHI TANABE PHARMA CORPORATION (JP) 2009-04-07 — — US disclosed
US-20060094724-A1 Fused furan compound MITSUBISHI TANABE PHARMA CORPORATION (JP) 2006-05-04 — — US disclosed
EP-1582521-A1 FUSED FURAN COMPOUND TANABE SEIYAKU CO., LTD. (JP) 2005-10-05 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150344473-A1 TANK-BINDING KINASE INHIBITOR COMPOUNDS TBKBP1, TNKS1BP1, TNKS NQO2 3186/4885ESR1 2773/4885ESR2 2241/4885
US-12377083-B2 Lysophosphatidic acid receptor antagonist and preparation method therefor LPAR1, LPAR2, LPAR4 NQO2 2933/4885ESR1 2301/4885ESR2 2535/4885
US-20220079928-A1 LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONIST AND PREPARATION METHOD THEREFOR LPAR1, LPAR2, LPAR4 NQO2 2933/4885ESR1 2301/4885ESR2 2535/4885
US-20250215029-A1 STAT MODULATORS AND USES THEREOF STAT6, STAT3, STAT5A NQO2 2509/4885ESR1 1293/4885ESR2 1086/4885
US-20090156803-A1 Condensed furan compounds F2, F12, F11 NQO2 888/4885ESR1 448/4885ESR2 1391/4885
US-20060094724-A1 Fused furan compound F2, F12, F11 NQO2 1698/4885ESR1 364/4885ESR2 1217/4885
US-20150011531-A1 INHIBITORS OF HIV REPLICATION MCM3, REV1, POLR2E NQO2 503/4885ESR1 2323/4885ESR2 2872/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.